Decreased expression of Cbl-B also enhances the effector functions of CD4+ T-cells and reduces the suppressive capacity of regulatory T-cells in patients with systemic lupus erythematosus and multiple sclerosis, indicating that Cbl-B is a clinically relevant negative regulator of T-cell driven inflammation (26, 27). Here, CBLB is linked to multiple sclerosis.